Aptose Biosciences Inc. (APTOF)

Market Cap	3.21M
Revenue (ttm)	n/a
Net Income (ttm)	-21.33M
Shares Out	n/a
EPS (ttm)	-19.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	773
Average Volume	6,051
Open	1.270
Previous Close	1.360
Day's Range	1.270 - 1.350
52-Week Range	0.636 - 17.100
Beta	0.92
RSI	42.10
Earnings Date	Aug 7, 2025

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, wh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 13
• Stock Exchange: OTCMKTS
• Ticker Symbol: APTOF